Medtronic https://medtronic.com recently announced their strategic partnership with BioIntelliSense https://biointellisense.com for the exclusive hospital and 30 day post-acute hospital-to-home distribution rights for the BioButton® multi-parameter wearable for continuous, connected monitoring.
The BioButton medical grade device measures up to 1,440 vital sign measurements per day which includes skin temperature, respiratory rate, and heart rate at rest. The device with advanced analytics can help clinicians to better detect early signs of patient deterioration or identify stable patients who may be candidates for earlier hospital discharge.
The rechargeable BioButton device also has configurable acute and post-acute modes to continuously monitor patients as they transition from higher to lower acuity settings. “Our vision is to empower clinicians and patients with actionable insights to personalize care at any time, or anywhere,” said Frank Chan Ph.D President of the Patient Monitoring business, which is part of the Medical Surgical Portfolio at Medtronic.
Dr. Chan further explains how their solutions touch more than 100 million patients annually in hospitals. “Through our collaboration with BioIntelliSense, we will support continuous connected care from in-hospital to home and expand our reach to help more patients in more places than ever before.”
In addition, with staffing shortages projected to reach 3.2 million healthcare workers by 2026, the Patient Monitoring business intends to continue to expand its HealthCast™ portfolio to improve workflow automation.
The HealthCast connectivity gateway helps increase workflow efficiency by connecting unconnected devices to EMRs and saves staff time by reducing the burden. The HealthCast VitalSync™ remote patient monitoring system enables clinicians to receive near real-time trend and alert data on web-enabled devices. By adding the use of the BioButton multi- parameter wearable to the HealthCast portfolio, Medtronic will be able to help even more patients.